Atea Pharmaceuticals, Inc.
ateapharma.comWhat Do They Do?
Develops oral antiviral drug candidates for hepatitis C and hepatitis E, including a hepatitis E treatment aimed particularly at immunocompromised patients.
10-K for FY2025, filed Mar 5, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$32.9MView ↗
- ▼ −11% (Loss)
- vs −$37.2M in Q2 FY2025
Pipeline focus
The earlier report centered on bemnifosbuvir for the coronavirus alongside its hepatitis C combination; the latest focuses on hepatitis C and adds a hepatitis E candidate, after ending coronavirus development.
10-K for FY2022, filed Feb 28, 2023 10-K for FY2025, filed Mar 5, 2026We are a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve…View ↗
Who Do They Compete With?
Competes with Gilead Sciences, AbbVie, and Merck
10-K for FY2025, filed Mar 5, 2026Sovaldi® (sofosbuvir) (Gilead Sciences, Inc.), an HCV nucleotide analog NS5B polymerase inhibitor approved for the treatment of adult…View ↗
Loading...
